Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25698017 | 0.86 | FABP3 (0.50) | CYP2D6MAPTTSHRSMN1; SMN2POLB | |
| SCHEMBL24070271 | 0.81 | KDM4E (0.41) | CYP2D6SMN1; SMN2KDM4EALDH1A1FABP3 | |
| SCHEMBL25698117 | 0.80 | AKT1 (0.40) | PIK3CA | |
| SCHEMBL24069432 | 0.80 | AKT1 (0.40) | PIK3CA | |
| SCHEMBL24069733 | 0.80 | PIK3CA (0.37) | NPSR1PIK3CA | |
| SCHEMBL25698253 | 0.79 | FFAR2 (0.34) | NPSR1CYP2D6ALDH1A1FABP3CYP2C9 | |
| SCHEMBL24069676 | 0.78 | MTOR (0.45) | — | |
| SCHEMBL24070710 | 0.78 | MTOR (0.45) | — | |
| SCHEMBL24070789 | 0.78 | SPR (0.48) | FABP3CYP2C9FABP4FABP5 | |
| SCHEMBL24069217 | 0.78 | SPR (0.41) | FABP3CYP2C9FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115551867-B | Fused tricyclic compounds, pharmaceutical compositions and uses thereof | 劲方医药科技(上海)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-115551867-A | Fused tricyclic compound, pharmaceutical composition and application thereof | 劲方医药科技(上海)有限公司 | 2022-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | NPSR1 4783/4885CYP1A2 360/4885CYP2D6 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.